A NOVEL CLINICAL CANCER RESEARCH MODEL FOR THE DEVELOPMENT OF YOUR PIPELINE

MEDSIR IS A LEADER IN CANCER CLINICAL RESEARCH COMMITTED TO HELPING BIOTECH COMPANIES IN THE DESIGN OF THE BEST STRATEGIES FOR THE DEVELOPMENT OF THEIR PIPELINE. MEDSIR MAKES THIS POSSIBLE THROUGH A NOVEL RESEARCH MODEL THAT PROVIDES THE BEST PERKS OF ACADEMIC RESEARCH AND THE MAIN ADVANTAGES OF COMPANY-SPONSORED RESEARCH

A NEW MODEL FOR DRUG CLINICAL DEVELOPMENT

MAIN DRAWBACKS OF TRADITIONAL
COMPANY-SPONSORED (CRO-BASED) MODEL

MAIN DRAWBACKS OF TRADITIONAL ACADEMIC/INVESTIGATOR-SPONSORED MODEL

Generation of a network of advisors is costly and time consuming

Delays in accrual and in the generation of data

MEDSIR’s network of oncology experts and KOLs can readily propose ideas for the development of your pipeline free of cost and with no commitment on your end

MEDSIR’s innovative model streamlines clinical research to speed up all processes of a clinical trial

RISK

SOLUTION

Limited capacity to generate clinical development ideas

Limited company involvement in study design and management

MEDSIR can give you access to proposals in different clinical settings from a pantumoral network of specialists in all liquid and solid tumors

MEDSIR’s favors a collaborative approach that considers the strategic interests of companies at all times, including continuous full data access

RISK

SOLUTION

Limited KOL engagement or scientific credibility

Limited capacity to rigorously manage all bureaucratic aspects of clinical research

MEDSIR studies are led by experts in the field, guaranteeing their personal engagement and increasing the consideration of the results in the scientific community

MEDSIR has a cross-functional structure integrating both scientific excellence and a professionalization of operational tasks to industry standards

RISK

SOLUTION

Lack of certainty regarding final CRO costs

Lack of operative reach outside of pre-defined collaborative structures

MEDSIR presents closed, milestone-based budgets where risk is shared

MEDSIR can work with the right sites for each trial anywhere in the world

RISK

SOLUTION

The 7 main challenges facing the biotech industry

DOWNLOAD

WHAT WE DO FOR HEALTHCARE COMPANIES

Strategic proposal for the clinical development of your drug presentation

Your pipeline is introduced to our KOLs
Definition of key settings with unmet clinical needs
Strategic clinical trial design
Collaborative discussion to include your strategic interests

SYNOPSIS APPROVAL

LOI SIGNED

FINAL CONTRACT

SIGNED

DELIVERY OF CLINICAL STUDY REPORT AND FINAL PUBLICATION

MEDSIR CAN BE OF INTEREST FOR YOU IF...

The pipeline of your biotech/pharma company contains products with potential application in oncology that are in clinical development (or about to start it), and you would like to receive insights from a network of experts and KOLs about the best, most cost-effective strategies to reach the market, with no prior commitment on your end.

Exploration of further scenarios to boost the development of your drug

Further development opportunities

Clinical trial full management
You can join the steering committee
Full data access
We can share publication rights

Clinical trial execution

Initial letter of intent signature
Study protocol generation
Preliminary operational activities
Milestone-based, full-service contract signature

Clinical trial set up

Timelines, sites, countries
Inclusion of the company’s operational preferences
Closed budgets with shared risk

Operational plan and budget construction

SCIENTIFIC AND OPERATIONAL EXCELLENCE

MEDSIR can help put young molecules on the right track or allow established molecules to consolidate drug positioning.

We can assist your company in the development of any health-related product, including drugs, diagnostic tools, technologies, etc.

We aim to streamline all types of clinical research by implementing organizational structures that improve human and economic resource efficiency, producing win-win situations for all parties involved.